

Katharina Seystahl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4345710/publications.pdf>

Version: 2024-02-01

27
papers

731
citations

687363

13
h-index

610901

24
g-index

27
all docs

27
docs citations

27
times ranked

1493
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2022, 35, 29-44.	2.0	4
2	Venous thromboembolic events in glioblastoma patients: An epidemiological study. <i>European Journal of Neurology</i> , 2022, 29, 2386-2397.	3.3	7
3	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	1
4	Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab048.	0.7	6
5	Distinct Cerebrovascular Reactivity Patterns for Brain Radiation Necrosis. <i>Cancers</i> , 2021, 13, 1840.	3.7	3
6	Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 1208-1209.	1.2	0
7	Cancer is associated with inferior outcome in patients with ischemic stroke. <i>Journal of Neurology</i> , 2021, 268, 4190-4202.	3.6	9
8	Endoglin and TGF- β 2 signaling in glioblastoma. <i>Cell and Tissue Research</i> , 2021, 384, 613-624.	2.9	7
9	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021, 23, 1100-1112.	1.2	59
10	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 659-670.	2.5	14
11	Crossed Cerebellar Diaschisis in Patients with Diffuse Glioma Is Associated with Impaired Supratentorial Cerebrovascular Reactivity and Worse Clinical Outcome. <i>Cerebellum</i> , 2020, 19, 824-832.	2.5	8
12	End-of-life care for glioma patients; the caregivers' perspective. <i>Journal of Neuro-Oncology</i> , 2020, 147, 663-669.	2.9	12
13	Hemodynamic investigation of peritumoral impaired blood oxygenation-level dependent cerebrovascular reactivity in patients with diffuse glioma. <i>Magnetic Resonance Imaging</i> , 2020, 70, 50-56.	1.8	5
14	Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14530-e14530.	1.6	0
15	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. <i>Neuro-Oncology</i> , 2019, 21, 234-241.	1.2	16
16	Biological Role and Therapeutic Targeting of TGF- β 3 in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1177-1186.	4.1	47
17	Pharmacotherapies for the treatment of glioblastoma " current evidence and perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1259-1270.	1.8	24
18	Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to ^{68}Ga -DOTATATE/-TOC uptake. <i>Neuro-Oncology</i> , 2016, 18, now060.	1.2	79

#	ARTICLE	IF	CITATIONS
19	Limited role for transforming growth factor β pathway activation-mediated escape from VEGF inhibition in murine glioma models. <i>Neuro-Oncology</i> , 2016, 18, 1610-1621.	1.2	27
20	Therapeutic options in recurrent glioblastoma—An update. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 389-408.	4.4	161
21	Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. <i>Neuro-Oncology</i> , 2016, 18, 1242-1252.	1.2	61
22	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407.	1.2	53
23	Differential regulation of TGF β -induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 254-265.	1.2	65
24	Development of a Short Sleeper Phenotype after Third Ventriculostomy in a Patient with Ependymal Cysts. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 211-213.	2.6	1
25	Neuropathological Characteristics of Progression after Prolonged Response to Bevacizumab in Multifocal Hemangioblastoma. <i>Oncology Research and Treatment</i> , 2014, 37, 209-212.	1.2	11
26	Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas. <i>European Neurology</i> , 2013, 69, 95-101.	1.4	27
27	Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 605-617.	4.1	24